U.S. Leisure Stock News

Why Goldman Sachs Group (GS) Is Back On Investors’ Radar Goldman Sachs Group (GS) is drawing fresh attention after recent share price moves, with the stock up around 10% over the past month and a modest gain in the past week. Investors are weighing this momentum against longer term returns and current fundamentals. See our latest analysis for Goldman Sachs Group. The recent 5.2% 7 day share price return and 10.2% 30 day share price return suggest momentum is rebuilding, set against a much...

In early 2026, Omega Healthcare Investors reported strong fourth-quarter results that topped analyst expectations, supported by improving rent coverage and more than US$200 million of new investments. A key development is Omega’s gradual move away from being a pure skilled nursing REIT toward a broader senior housing focus, which could meaningfully reshape its income mix and risk profile over time. We'll now examine how Omega's better-than-expected quarter and expanding investment activity...

Lumentum Holdings (NasdaqGS:LITE) plans to exchange approximately US$474.6 million of outstanding convertible senior notes for about 5.7 million newly issued common shares. The transaction is aimed at adjusting the company’s capital structure by reducing outstanding debt and increasing the equity base. The exchange is expected to affect shareholder composition as noteholders become equity holders. Lumentum focuses on optical and photonic products that serve communications, 3D sensing, and...

If you are wondering whether Stifel Financial's current share price reflects its true worth, the recent track record gives you plenty to think about. The stock last closed at US$77.24, with returns of 4.3% over the past week, 6.3% over the past month, a 9.7% decline year to date, and a 43.6% gain over the past year, alongside 104.4% and 81.1% returns over the past 3 and 5 years respectively. Recent coverage has focused on Stifel Financial in the context of ongoing capital markets activity...

Short term share performance check Blue Owl Capital (OWL) has seen its share price move lower in recent periods, with a 0.6% decline over the past day, a 4.0% decline over the past week, and a month performance of 8.8% lower. Looking further back, the stock shows a past 3 months return of 47.7% lower, a year to date return of 46.2% lower, and a 1 year total return of 48.8% lower, providing context for assessing recent trading levels. See our latest analysis for Blue Owl Capital. With the...

Centers for Medicare & Medicaid Services finalized 2027 Medicare Advantage rate increases that are higher than previously signaled. Payment updates and a delay to certain risk model changes are expected to provide more predictable revenue per enrollee for issuers like Elevance Health. The decision follows a period of pressure on government plans and is a key input for Elevance Health’s medium term planning. For Elevance Health (NYSE:ELV), this policy shift comes at a time when the stock is...

If you are wondering whether Procter & Gamble is offering fair value at today’s price or if the market is mispricing this consumer staples giant, this breakdown helps you weigh what you are really paying for each share. The stock last closed at US$145.16, with returns of 1.4% over 7 days, a 5.3% decline over 30 days, 2.4% year to date, and a 10.6% decline over 1 year. This performance may have some investors reassessing both risk and opportunity. Recent coverage has focused on Procter &...

CrowdStrike Holdings (CRWD) is back in focus after Anthropic’s powerful AI agents rattled cybersecurity valuations. At the same time, the company secured a higher profile in Anthropic partnerships and expanded its share buyback authorization. See our latest analysis for CrowdStrike Holdings. The recent AI driven volatility has left CrowdStrike’s short term moves under pressure, with a 30 day share price return of a 14.25% decline and year to date share price return of a 16.44% decline, yet...

If you are wondering whether EQT at around US$58.68 is still offering value or starting to look fully priced, this breakdown is designed to help you weigh that up with clear numbers. The stock’s recent performance has been mixed, with a 1.7% decline over 7 days and an 8.1% decline over 30 days. However, a 9.8% gain year to date and 19.6% over 1 year keep longer term returns in focus. Recent headlines around EQT have concentrated on its role in the U.S. natural gas sector and shifting...

POET Technologies (POET) reported full year 2025 results, with sales of US$1.07 million and a net loss of US$62.96 million. Basic and diluted loss per share from continuing operations improved to US$0.68. See our latest analysis for POET Technologies. The earnings release appears to have shifted sentiment, with the share price up 15.79% on the day to US$7.04 and a 7 day share price return of 15.22%. The 1 year total shareholder return of 88.74% contrasts with weaker recent 30 and 90 day share...

Humana (NYSE:HUM) has partnered with b.well Connected Health to launch an interoperability platform for secure, real-time sharing of patient health data. The platform is designed to link providers, health plans, and digital tools, giving individuals more control over their health information. The initiative supports federal goals for data transparency and interoperability while aiming to simplify administrative workflows. Humana enters this data initiative with shares at $192.15 and a mixed...

If you are wondering whether Guidewire Software at around US$117.95 offers value or just more volatility, you are not alone. That is exactly what this breakdown will address. The stock has seen sharp moves recently, with a 21.8% decline over the last 7 days, a 25.5% decline over 30 days, and a 37.1% decline year to date, while the 3 year and 5 year returns sit at 51.3% and 12.0% respectively. These price swings have kept Guidewire on many investors' watchlists, as the market reassesses what...

Why Rambus Is On Investors’ Radar Today Rambus (RMBS) is drawing attention after a recent stretch of positive stock performance, with the share price up over the past week, month, and past 3 months. This has prompted closer scrutiny of its current valuation. See our latest analysis for Rambus. The recent 4.6% 1 day share price return and 18.7% 7 day share price return follow a year where total shareholder return is reported at 134.8%, with multi year total shareholder returns also firmly...

Waters (WAT) has attracted attention after recent share price moves, with a 7.5% gain over the past month contrasting with a 19.3% decline over the past 3 months and softer 1 year returns. See our latest analysis for Waters. Viewed together, the recent 7-day share price return of 5.18% and 30-day share price return of 7.55% come after a 90-day share price decline of 19.34%. Meanwhile, the 1-year total shareholder return of a 1.61% decline and 5-year total shareholder return of 6.70% suggest...

In early April 2026, Back to the Roots announced an expanded ninth-year partnership with Target, making it the exclusive organic seed brand across about 1,800 stores and Target.com, while MUSH Foods unveiled new protein-focused launches at Target as part of a broader national retail push. Together with Target’s multibillion-dollar store remodel program, baby department upgrades, and expanded next-day delivery using Shipt, these partnerships highlight how the retailer is reshaping its...

NovoCure (NasdaqGS:NVCR) has combined its medical and innovation leadership under one executive. Uri Weinberg now holds dual roles as Chief Medical Officer and Chief Innovation Officer. The move centralizes responsibility for clinical direction and product development. NovoCure, trading at a recent share price of $10.58, has gone through a difficult stretch, with the stock showing a 19.4% decline year to date and a 35.9% decline over the past year. Over a 3 year period, the share price...

Jones Trading has initiated coverage on AbCellera Biologics (ABCL) with an optimistic view, drawing fresh attention to the antibody drug developer and prompting investors to reassess the stock’s risks, pipeline, and recent share performance. See our latest analysis for AbCellera Biologics. At a share price of US$3.54, AbCellera Biologics has seen a 2.91% 1 day share price return and a 90 day share price return decline of 18.99%, while the 1 year total shareholder return of 47.5% contrasts...

L3Harris Technologies (LHX) is back in the spotlight after powering NASA’s Artemis II crewed lunar mission and teaming up with Xoople on an AI era satellite constellation, drawing fresh attention to the stock. See our latest analysis for L3Harris Technologies. Despite a 1-day share price decline of 1.22% and a softer 1-month share price decline of 2.93%, L3Harris trades at US$353.59. Its 1-year total shareholder return of 61.98% and 3-year total shareholder return of 87.57% indicate momentum...

Riot Platforms (NasdaqCM:RIOT) has approved a phased declassification of its Board of Directors. The company plans to move to annual director elections beginning in 2029. The change follows strong shareholder support for greater board accountability and transparency. Riot Platforms, a Bitcoin mining and infrastructure company, is making a governance shift that gives shareholders a more regular say on who sits in the boardroom. The move to annual director elections, once fully in place,...

Sigma Lithium Corporation recently reported full-year 2025 results, with sales of US$110.01 million versus US$151.35 million in 2024 and a net loss of US$50.19 million, while also issuing multi-year production guidance through 2028. An interesting takeaway is that, despite lower sales and continuing losses, Sigma Lithium laid out a phased plan to lift output from 240,000 tonnes in 2026 to 770,000 tonnes by 2028, signaling a clear focus on scaling operations. We’ll now examine how Sigma...

Uxin (NasdaqGS:UXIN) has reported its FY 2025 third quarter with revenue of C¥879.3 million and a basic EPS loss of C¥0.30, setting the tone for how investors assess the latest stretch of trading against a current share price of C¥2.97. The company has seen quarterly revenue move from C¥401.2 million in FY 2024 Q2 to C¥879.3 million in FY 2025 Q3. Basic EPS has ranged from a loss of C¥0.48 in FY 2024 Q4 to a loss of between C¥0.27 and C¥0.35 across the FY 2025 quarters so far, and those...

Why the DOJ settlement matters for Live Nation Entertainment (LYV) Live Nation Entertainment (LYV) has just resolved a U.S. Department of Justice antitrust lawsuit, accepting operational changes that remove the threat of a structural breakup and have helped support recent stock gains. See our latest analysis for Live Nation Entertainment. The DOJ settlement has come alongside a strong run in the stock, with a 9.9% five day share price gain reported recently and a 90 day share price return of...

In early April 2026, analyst commentary from UBS and TD Cowen pointed to rising oil-linked input costs and inflationary pressures as key challenges for Church & Dwight’s earnings outlook. This shift in analyst focus highlights how cost inflation and weaker pricing power could pressure profitability even as consumer demand trends remain supportive. We’ll now examine how concerns about higher oil-related input costs might reshape Church & Dwight’s existing investment narrative and risk...

Wondering whether J. M. Smucker at around US$90.91 is a value opportunity or a value trap? This article breaks down what the current price might actually be telling you. The stock has recently been under pressure, with returns of a 4.8% decline over the past week, a 15.5% decline over the last month, a 5.9% decline year to date, an 18.4% decline over one year, a 33.4% decline over three years, and an 18.4% decline over five years. These moves come as investors reassess J. M. Smucker's long...